openPR Logo
Press release

PD-1 and PD-L1 Inhibitors Competitive Landscape, Pipeline and Market Analysis, 2017

08-21-2017 02:25 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

PD-1 and PD-L1 Inhibitors Competitive Landscape, Pipeline

Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1) is the most talked about immuno-oncology target. Programmed Death 1 (PD-1) is an immune inhibitory receptor expressed on several immune cells, particularly cytotoxic T cells. Therapeutics that blocks this interaction has demonstrated promising clinical activity in several tumor types. PD-L1 not only provides the immune escape of tumor cells but also stimulate apoptosis switch on activated T cells.

According to DelveInsight’s report “PD-1 and PD-L1 Inhibitors Competitive Landscape, Pipeline and Market Analysis, 2017”, currently there are about five marketed drugs in this arena and more than 50 products are in the pipeline in various development stages. Products that are in the phase III of development and about to enter the market are – PDR001 (Novartis), REGN2810 (Regeneron), SHR1210 (Incyte). Drugs that are used for this therapy have different molecular types like proteins, fusion proteins, antibody, monoclonal antibody, small molecule, siRNA etc, depending on their derived sources. Also, the route of administration can be subcutaneous, intravenous or oral.

As per the details provided in the report by DelveInsight, companies are working on different technologies for developing drugs in the respective domain, example of such technologies are 3D antigen design technology (Tikcro Technologies), Affimer Technology (Avacta Life Sciences), Avidocin Technology (Merus), Bispecific Fc Domains Technology (Xencor) etc. Currently, maximum products are in pre clinical phase showing the increased interest of companies in the given arena.

DelveInsight’s latest report has covered the complete PD-1 and PD-L1 Inhibitors domain. Complete insight about all the marketed drugs and pipeline products along with the different technologies being used by the companies in the PD-1 and PD-L1 arena is provided. Information about the future products that are about to enter the market and can change the present market scenario, drug profiling of the current marketed products and dormant product information is also covered.

Also, the complete coverage of ASCO 2017 including the latest addition in the market, existing drug achievements and clinical trial results of different drugs is a fringe benefit for the companies and institutes working for the advancement of the respective technology.

Reasons to buy:

• The report provides competitive pipeline landscape of PD-1 and PD-L1 Inhibitors.
• The report provides information about the pipeline products and drug profiling of the marketed drugs, MOA, dormant products.
• The report covers the latest technologies that are being used by different companies.
• Pipeline product coverage based on various stages of development ranging from discovery stage till late stage products.
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type.

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. We support companies by providing end to end comprehensive solutions to improve their performance and in making long lasting decision for their businesses.

We advise leading decision makers on their critical issues and opportunities; Research & Development, Strategy Making, Commercial, Operations, Competitive Intelligence, Competitive Landscaping and Mergers & Acquisition across all the Pharma and Biotech industries and geographies. We serve our clients by delivering practical and enduring results, and equipping our clients to grow and lead.

DelveInsight
New Delhi
India

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release PD-1 and PD-L1 Inhibitors Competitive Landscape, Pipeline and Market Analysis, 2017 here

News-ID: 677194 • Views:

More Releases from DelveInsight Business Research

Bartonellosis Market Analysis 2032: Epidemiology, Market Size, Share, Treatment Options, Clinical Trials, Leading Companies & Growth Trends by DelveInsight
Bartonellosis Market Analysis 2032: Epidemiology, Market Size, Share, Treatment …
(New York, USA) DelveInsight's "Bartonellosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Bartonellosis, historical and forecasted epidemiology as well as the Bartonellosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Bartonellosis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Bartonellosis market size from 2019 to
Atypical Hemolytic Uremic Syndrome Market Forecasted to Expand by 2032, Projected by DelveInsight | Key Players Include Omeros Corporation, Akari Therapeutics, Alexion Pharmaceuticals, Novartis Pharmaceuticals, Hoffmann-La Roche, and Chugai Pharmaceutical
Atypical Hemolytic Uremic Syndrome Market Forecasted to Expand by 2032, Projecte …
(Albany, USA) DelveInsight's "Atypical Hemolytic Uremic Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Atypical Hemolytic Uremic Syndrome, historical and forecasted epidemiology as well as the Atypical Hemolytic Uremic Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Atypical Hemolytic Uremic Syndrome market report provides current treatment practices, emerging drugs, the market share of the individual therapies,
Hyperhidrosis Market Forecast 2032: Epidemiological Insights, Market Dynamics, Therapeutic Innovations, Clinical Trial Landscape by DelveInsight | Leading Companies - Botanix Pharmaceuticals, GSK Plc, Allergan, Brickell Biotech, Atacama
Hyperhidrosis Market Forecast 2032: Epidemiological Insights, Market Dynamics, T …
(New York, USA) DelveInsight's "Hyperhidrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Hyperhidrosis, historical and forecasted epidemiology as well as the Hyperhidrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The report on the Hyperhidrosis market presents up-to-date treatment practices, emerging drugs, the market share of different therapies, and the present and projected size of the Hyperhidrosis market
Projected Expansion in Chronic Lymphocytic Leukemia Market Forecasted by 2032, DelveInsight Predicts | Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG Therapeutics, Bristol Myers Squibb, Novar
Projected Expansion in Chronic Lymphocytic Leukemia Market Forecasted by 2032, D …
(New York, USA) DelveInsight's "Chronic Lymphocytic Leukemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Chronic Lymphocytic Leukemia, historical and forecasted epidemiology as well as the Chronic Lymphocytic Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Chronic Lymphocytic Leukemia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current

All 5 Releases


More Releases for Inhibitors

Immune Checkpoint Inhibitors Market: Current Evidence And Future Perspectives Of …
Stratagem Market Insights delivers key insights for the Immune Checkpoint Inhibitors market in its published report, which include global industry analysis, Size, Growth, Opportunities, Emerging Trends, Challenges, and Geographic Regions over the forecast period (2021-2028). In terms of revenue, the global Immune Checkpoint Inhibitors market is projected to grow at a CAGR of XX% during the forecast period, owing to several factors about which SMI offers detailed insights and forecasts
Vesicular Monoamine Transporter-2 Inhibitors (VMAT2 Inhibitors) Market to Regist …
Vesicular monoamine transporter 2 (VMAT2) is a membrane-embedded protein that is responsible for uptake of monoamines neurotransmitters such as dopamine, serotonin, norepinephrine, and histamines into the synaptic vesicles in monoaminergic neurons. Vesicular monoamine transporter proteins 2 are expressed in the central nervous system (CNS) and plays the crucial role in the signaling process between the monoamine neurons. VMAT2 is the only transporter that carries the cytoplasmic dopamine into the vesicles.
Crude Oil Flow Improvers Market by Type (Paraffin Inhibitors, Asphaltene Inhibit …
Global Crude Oil Flow Improvers Market was valued at $1,282 million in 2016, and is anticipated to reach $1,920 million, growing at a CAGR of 5.7% from 2017 to 2023. Crude oil is one of the most actively traded commodities with a stable growth rate globally. It is extracted from remote locations and needs to be transported through pipelines. Transportation of crude oil via pipeline is relatively difficult, owing to
Immune Check Point Inhibitors Market Immune Check Point Inhibitors Clinical Pipe …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Immune Checkpoint Inhibitors- Introduction to Next Generation Cancer Immunotherapy 1.1 Overview 1.2 History- From Tragedy to Breakthrough Major Immune Checkpoints Proteins 2.1 Role of Cytotoxic T lymphocyte Antigen-4 (CTLA-4) in Cancer Development 2.2 Role of Programed Cell Death Protein 1 (PD1) in Cancer Development Mechanism of Action of Immune Checkpoint Inhibitors 3.1 Cytotoxic T lymphocyte Antigen-4
Global Immune Check Point Inhibitors Market & Immune Check Point Inhibitors Clin …
Immunotherapy represents a paradigm shift in oncology therapy along the multiple fronts. Although, targeted therapy upgrades the underlying signaling defect which results in oncogenesis within the tumor. The immune checkpoint blockade is fundamentally a therapy which directed at the patient's native immune system to tilt the immune homeostasis away from self-tolerance towards cytotoxicity, with the goal of inducing antitumor immunity. The immune checkpoint inhibitors such as ipilimumab, nivolumab and pembrolizumab
Tumor Necrosis Factor Inhibitors Market & TNF Inhibitors Clinical Pipeline Outlo …
The search for the effective therapeutic approaches in the modulation of the TNF has been focus of the research efforts. Approximately 1 Million people in the worldwide either undergoing the treatment or have been treated with the TNF inhibitors which are available in the pharmaceutical market which surrounding the indications that include the rheumatoid arthritis, psoriatic arthritis, psoriasis and inflammatory bowel diseases. The neutralization of the TNF signaling can be achieved